LENZ Therapeutics (LENZ) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tenaya Therapeutics (TNYA) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 70.3% versus a loss of 92.7%. Over five years, LENZ leads with a -96.0% price change compared with -97.4% for TNYA. Tenaya Therapeutics is the larger company by market cap ($122.0 million vs $110.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | TNYA |
|---|---|---|
| Share price | $3.53 | $0.5442 |
| Market cap | $110.91M | $122.03M |
| 1-day change | -2.49% | +2.02% |
| YTD return | -77.94% | -23.57% |
| 1-year return | -92.74% | -70.26% |
| 5-year return | -95.95% | -97.35% |
| EPS (TTM) | $-4.13 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $49.16 | $2.35 |
| 52-week low | $3.35 | $0.5211 |
| Distance from 52-week high | -92.82% | -76.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +579.89% | +488.02% |
| Average volume | 829.74K | 2.26M |
| Shares outstanding | 31.42M | 224.23M |
| Employees | 152 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNYA has outperformed LENZ by 22.5 percentage points over the past year.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 152 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
LENZ vs TNYA FAQ
Which is bigger, LENZ Therapeutics or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $122.03M compared with $110.91M for LENZ Therapeutics (LENZ).
Which stock has performed better over the past year, LENZ or TNYA?
TNYA returned -70.26% over the past 12 months, compared with -92.74% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.